Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul-Cerrahpasa , Istanbul, Turkey.
Cerrahpasa Medical Faculty, University of Istanbul-Cerrahpasa , Istanbul, Turkey.
Immunol Invest. 2021 Feb;50(2-3):273-281. doi: 10.1080/08820139.2020.1751195. Epub 2020 Apr 22.
: Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is a monocyte and neutrophil receptor functioning in innate immunity. TREM-1 activity has been studied in various autoimmune diseases such as RA and SLE but there is no data in autoinflammatory pathologies. We studied soluble TREM-1 (sTREM-1) activity in Familial Mediterranean Fever (FMF) cases to evaluate the clinical role of TREM-1 in amyloidosis. : The study includes 62 patients with FMF (42 with amyloidosis) who are regular attendees of a tertiary center for autoinflammatory diseases. For control purposes, 5 patients with AA amyloidosis secondary to other inflammatory diseases, and 20 healthy individuals were also included. Soluble TREM-1 levels were measured using enzyme-linked immunosorbent assay (ELISA). All FMF patients were in an attack-free period during the collection of the blood samples.: Soluble TREM-1 levels were found to be significantly higher in the FMF amyloidosis group compared to FMF without amyloidosis group and healthy controls ( = .001 and 0.002). Nevertheless, this difference between sTREM-1 levels was not found among FMF amyloidosis and other AA amyloidosis groups ( = .447) as well as between only FMF patients and healthy controls ( = .532). Soluble TREM-1 levels were found in correlation with creatinine and CRP in the FMF patient group regardless of their amyloidosis diagnosis (r = 0.314, = .013; r = 0.846, < .001).: TREM-1 seems to be related to renal function rather than disease activity in FMF. Its role as an early diagnostic marker of amyloidosis in FMF complicated with AA amyloidosis should be tested in larger patient groups.
: 髓系细胞触发受体-1（TREM-1）是一种存在于单核细胞和中性粒细胞表面的受体，在固有免疫中发挥作用。TREM-1 的活性已在各种自身免疫性疾病（如 RA 和 SLE）中得到研究，但在自身炎症性疾病中尚无相关数据。我们研究了家族性地中海热（FMF）患者可溶性 TREM-1（sTREM-1）的活性，以评估 TREM-1 在淀粉样变性中的临床作用。 : 该研究纳入了 62 名 FMF 患者（42 名合并淀粉样变性），他们均为自身炎症性疾病三级中心的定期就诊者。为了对照目的，还纳入了 5 名因其他炎症性疾病引起的 AA 淀粉样变性患者和 20 名健康对照者。采用酶联免疫吸附试验（ELISA）测定可溶性 TREM-1 水平。所有 FMF 患者在采集血样时均处于无发作期。: 结果发现，FMF 淀粉样变性组的可溶性 TREM-1 水平明显高于 FMF 无淀粉样变性组和健康对照组（=0.001 和 0.002）。然而，FMF 淀粉样变性组与其他 AA 淀粉样变性组之间的 sTREM-1 水平差异无统计学意义（=0.447），FMF 患者与健康对照组之间的差异也无统计学意义（=0.532）。在 FMF 患者组中，无论其是否患有淀粉样变性，可溶性 TREM-1 水平均与肌酐和 CRP 相关（r=0.314，=0.013；r=0.846，<0.001）。: 在 FMF 中，TREM-1 似乎与肾功能有关，而与疾病活动无关。在合并 AA 淀粉样变性的 FMF 患者中，其作为淀粉样变性早期诊断标志物的作用需要在更大的患者群体中进行检验。
